// App-Quantinova.ai

: Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Researchers

Presenter

  • Alison J. Moskowitz

Principal Investigators

  • Armando Santoro

  • Giuseppe Gritti

  • Pauline Brice

  • David Cunningham

  • Paul Barr

  • Justin Kline

  • John Kuruvilla

  • Nathalie A Johnson

  • Neha Mehta-Shah

  • Thomas Manley

  • Manish Sharma

  • Stephen Francis

  • Joseph Cohen

  • Pier Luigi Zinzani

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Istituto Clinico Humanitas, Rozzano,

  • Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

  • Hospital Saint Antoine, Paris, France

  • The Royal Marsden Hospital, London, United Kingdom

  • University of Rochester, Rochester, NY

  • The University of Chicago Medical Center, Chicago, IL

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Oncology, Jewish General Hospital, Montreal, QC, Canada

  • Washington University School of Medicine, St. Louis, MO

  • Seattle Genetics, Bothell, WA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Institute of Hematology “Seràgnoli' Bologna University,Bologna,Italy

Locations

  • United States

  • Italy

  • France

  • United Kingdom

  • Canada

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Cluster of Differentiation 30

Drug/Treatment

  • Adcetris

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multinational

  • Cohort

Phase

  • II

Study Id's

  • NCT02581631

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved